Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
Abstract Glycated hemoglobin (HbA1c) is widely accepted as the most reliable measure of long‐term glycemia. However, there is disagreement among professional medical societies on a proper glycemic target for long‐term benefits in type 2 diabetes (T2D). The use of some glucose‐lowering drugs was asso...
Main Authors: | Masayuki Ikeda, Rumiko Shimazawa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | Journal of General and Family Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/jgf2.244 |
Similar Items
-
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
by: Rumiko Shimazawa, et al.
Published: (2019-11-01) -
The Role of Glycated Hemoglobin in the Diagnosis and Monitoring of Diabetes Mellitus
by: L.А. Lutsenko
Published: (2014-09-01) -
The Role of Glycated Hemoglobin in the Diagnosis and Monitoring of Diabetes Mellitus
by: L.А. Lutsenko
Published: (2014-10-01) -
Modern approaches to the treatment of type 2 diabetes mellitus
by: T. V. Morgunova, et al.
Published: (2018-03-01) -
Mean glycosylated hemoglobin in children with type 1 diabetes at King Fahad Medical City, Riyadh, Saudi Arabia
by: Abdulhameed Y Alsaheel, et al.
Published: (2020-01-01)